A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.

Author(s): van Laar T, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA

Affiliation(s): Department of Neurology, Leiden University Hospital, The Netherlands.

Publication date & source: 1993-09, Clin Neurol Neurosurg., 95(3):231-5.

Publication type: Clinical Trial; Randomized Controlled Trial

Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected for a randomized double-blind placebo-controlled study, concerning the clinical effects of subcutaneous apomorphine and its assessment in 'off'-periods. The study was designed as five n = 1 studies, in which every patient was his own control. The effect of apomorphine was studied by using the Columbia rating scale and quantitative assessments, using tapping, walking and pinboard. There was a significant positive effect of apomorphine, in a mean optimal dose of 2.7 mg, with a mean latency of onset of 7.3 min and a mean duration of response of 96 min. After pretreatment with domperidone, no significant adverse effects were observed. Tapping showed the highest correlation with rigidity and bradykinesia. Walking showed a high correlation with stability and gait. Pinboard testing did not give additional information. The first conclusion was that apomorphine proved to be a significantly effective dopamine agonist, proven now also by a double blind placebo-controlled study. Secondly it was concluded that assessment of clinical effect in parkinsonian patients can be performed best by combining the Columbia item tremor with tapping and walking scores.